Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Sells IVD Business for $20M as Part of Plan to Focus on PGx Rx and Dx Plays

NEW YORK (GenomeWeb News) — Clinical Data today said it has sold its Netherlands-based in vitro diagnostics business Vital Scientific to French company ELITech Group for $19.5 million in cash.
The actual sale price was $15 million, but Clinical Data said it retained $4.5 million in cash from Vital Scientific immediately before the sale.
CEO Drew Fromkin said the divestiture is “the latest and most significant step” in Clinical Data’s plan to “devote all of our resources to our IP-driven pharmacogenomics tests and targeted therapeutics, as well as our genomics services division.”
ELITech President Pierre Debiais said the acquisition is important to his firm because “it complements the company's current portfolio of IVD products and, in particular, its clinical reagents business.”
Clinical Data said this is the third move it has made to let go of its IVD enterprises. The company last November sold its Australia-based Vital Diagnostics business for $1 million, and in June this year it sold its US-based Clinical Data Sales and Service arm for around $7 million.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.